Skip to main content
Top
Published in: Ophthalmology and Therapy 1/2024

Open Access 08-11-2023 | ORIGINAL RESEARCH

VIVEX: A Formula for Calculating Individual Vitreous Volume: A New Approach Towards Tailored Patient Dosing Regime in Intravitreal Therapy

Authors: Andreas F. Borkenstein, Eva-Maria Borkenstein, Achim Langenbucher

Published in: Ophthalmology and Therapy | Issue 1/2024

Login to get access

Abstract

Introduction

Personalized medicine and patient-tailored drug dosing have been substantiated through thousands of clinical studies, demonstrating their safety and efficacy. The principle: “as much as necessary, as little as possible” is widely spread. Quantities and doses are therefore adjusted individually. This is not the case for intravitreal injections in the context of retinal diseases. Intravitreal injections are not adjusted in relation to the vitreous volume. The vitreous body is described as “approx. 4 cm3” in the literature.

Methods

In this retrospective observational study, we included 72 eyes of patients who had undergone magnetic resonance imaging (MRI) of the orbit and biometry measurements of the anterior chamber depth (ACD) and axial length. After segmentation of the volume data, the vitreous volume was extracted by voxel integration, and a simple prediction model was derived to determine the vitreous volume from the axial length (AL) measurement with AL3·π/6·(0.76 + 0.012·(AL-24). This is the volume of a sphere AL3·π/6 and a correction term 0.76 + 0.012·(AL-24) to account for the portion of the vitreous in the entire globe and the proportional increase of the vitreous portion for long (myopic) eyes.

Results

Emmetropic eyes with an axial length of 22.50–23.50 mm had a vitreous volume of around 4.5–5.5 cm3. Myopic eyes with an axial length of 30.00 mm had a calculated vitreous volume of 9.0–10.0 cm3. Hypermetropic eyes with an axial length of 20.00 mm showed a vitreous volume of 3.0–4.0 cm3.

Conclusions

By implementing the new calculation formula on the IOLCON website, it will be easy to get the exact individual vitreous volume. The data could be used by retinal surgeons prior to surgery. The knowledge of anatomical dimensions and exact individual vitreous volume seems to be important for gas and silicone oil fillings. With the newly derived knowledge, multicentric studies can evaluate the impact of the dose in intravitreal therapies. Patient-tailored dosing could prevent side effects and improve effectiveness.
Literature
11.
go back to reference Nanji K, Sarohia GS, Kennedy K, Ceyhan T, McKechnie T, Phillips M, Devji T, Thabane L, Kaiser P, Sarraf D, Garg SJ, Sivaprasad S, Wykoff CC, Bakri SJ, Sheidow T, Bhandari M, Chaudhary V. The 12- and 24-month effects of intravitreal ranibizumab, aflibercept, and bevacizumab on intraocular pressure: a network meta-analysis. Ophthalmology. 2022;129(5):498–508. https://doi.org/10.1016/j.ophtha.2021.11.024. (Epub 2021 Dec 4 PMID: 34871637).CrossRefPubMed Nanji K, Sarohia GS, Kennedy K, Ceyhan T, McKechnie T, Phillips M, Devji T, Thabane L, Kaiser P, Sarraf D, Garg SJ, Sivaprasad S, Wykoff CC, Bakri SJ, Sheidow T, Bhandari M, Chaudhary V. The 12- and 24-month effects of intravitreal ranibizumab, aflibercept, and bevacizumab on intraocular pressure: a network meta-analysis. Ophthalmology. 2022;129(5):498–508. https://​doi.​org/​10.​1016/​j.​ophtha.​2021.​11.​024. (Epub 2021 Dec 4 PMID: 34871637).CrossRefPubMed
Metadata
Title
VIVEX: A Formula for Calculating Individual Vitreous Volume: A New Approach Towards Tailored Patient Dosing Regime in Intravitreal Therapy
Authors
Andreas F. Borkenstein
Eva-Maria Borkenstein
Achim Langenbucher
Publication date
08-11-2023
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2024
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-023-00838-2

Other articles of this Issue 1/2024

Ophthalmology and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.